Try our beta test site
402 studies found for:    myelodysplastic syndrome | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
2 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
3 Recruiting Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Conditions: Adult;   Myelodysplastic Syndromes
Interventions: Other: questionnaire administration;   Other: fatigue assessment and management;   Other: observation;   Other: quality-of-life assessment
4 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
5 Recruiting The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention:
6 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
7 Recruiting Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Biological: MEDI4736 Evaluate MEDI4736 in MDS;   Drug: VIDAZA;   Biological: tremelimumab
8 Recruiting 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
9 Recruiting PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.
Condition: Myelodysplastic Syndromes
Interventions: Other: research of disease-related factors;   Other: research of comorbidities;   Other: physical performance
10 Recruiting Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: CC-486 (ORAL AZACITIDINE);   Drug: Durvalumab
11 Recruiting An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions: Drug: Azacitidine;   Drug: Durvalumab
12 Recruiting Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Tipifarnib
13 Recruiting Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Interventions: Drug: Sertraline;   Procedure: Bone Marrow Aspirate/Biopsy
14 Recruiting Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Conditions: Acute Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Interventions: Other: Blood sampling;   Other: Bone marrow aspirate;   Other: Skin biopsy;   Other: Buccal swab
15 Recruiting Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: DSP-7888
16 Not yet recruiting A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Condition: Myelodysplastic Syndromes (MDS)
Interventions: Drug: venetoclax;   Drug: azacitidine
17 Recruiting The National Myelodysplastic Syndromes (MDS) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic
18 Recruiting Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Procedure: Best Supportive Care;   Drug: BI 836858
19 Recruiting A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: OPN-305
20 Recruiting CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Condition: Previously Treated Myelodysplastic Syndromes
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.